$Daxor (DXR.US)$
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Tuesday, 4th March at 8:00 am
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today the filing of i...

$Daxor (DXR.US)$
This groundbreaking research represents a significant advancement in heart failure management and strengthens Daxor's market position in diagnostic technology. The discovery that 20% of advanced heart failure patients have a previously unrecognized blood volume condition creates substantial market opportunities:
The identification of this specific phenotype in 700,000-1,400,000 US patients represents a significant expansion of Daxor's addressable market....

$Daxor (DXR.US)$
Hidden Heart Failure Risk Affects Millions: Daxor's Revolutionary Blood Test Unlocks Life-Saving Treatment Path

$Daxor (DXR.US)$
Major Clinical Study: Revolutionary Heart Failure Diagnostic Achieves Near-Perfect Accuracy

$Daxor (DXR.US)$ DAXOR'S INNOVATIVE BVA-100 BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
GlobeNewswire· 
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence
Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Confere...

$Daxor (DXR.US)$
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to impro...

$Daxor (DXR.US)$
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri...

$Daxor (DXR.US)$
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...

Hello everyone,
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor (DXR.US)$

$Daxor (DXR.US)$ slow and steady volume increase.   Microfloat, lots of good news, will be a runner when she gets found